{"status": "ok", "totalResults": 2, "articles": [{"source": {"id": null, "name": "Interesting Engineering"}, "author": "Loukia Papadopoulos", "title": "A brain scientist and a philosopher have resolved a 25-year-old wager on consciousness - Interesting Engineering", "description": "A 25-year-old wager on the source of consciousness between German-American computational neuroscientist Christof Koch and Australian philosopher and cognitive scientist David Chalmers has come to a close.", "url": "https://interestingengineering.com/science/a-brain-scientist-and-a-philosopher-have-resolved-a-25-year-old-wager-on-consciousness", "urlToImage": "https://dnd2oi6izkvoi.cloudfront.net/2023/06/27/image/jpeg/OisZJ6nz4wycsQ2LtmimD2MZzTKcJo4bu5gwYQrE.jpg", "publishedAt": "2023-06-27T12:09:00Z", "content": "Indeed, consciousness was a whole other issue that Chalmers famously divided into \"easy problems\" and \"hard problems\".\r\nExamples of easy problems are straight-forward to define such as integrating in\u2026 [+819 chars]"}, {"source": {"id": null, "name": "Healio"}, "author": null, "title": "Dupilumab decreases exacerbation rate, improves lung function in COPD type 2 inflammation - Healio", "description": "WASHINGTON &mdash; At 52 weeks, adults with moderate/severe COPD and type 2 inflammation receiving dupilumab had a lower exacerbation rate and better lung function, according to an American Thoracic Society International Conference presentation.&ldquo;Dupilum\u2026", "url": "https://www.healio.com/news/pulmonology/20230627/dupilumab-decreases-exacerbation-rate-improves-lung-function-in-copd-type-2-inflammation", "urlToImage": "https://www.healio.com/~/media/slack-news/stock-images/pulmonology/c/copd_adobe-stock.jpg", "publishedAt": "2023-06-27T12:08:46Z", "content": "Source/Disclosures\r\n Source: Rabe KF, et al. Scientific Symposium. B13. Breaking news: Clinical trial results in pulmonary medicine. Presented at: American Thoracic Society International Conference; \u2026 [+10000 chars]"}]}